| Company Name: |
LGM Pharma |
| Tel: |
1-(800)-881-8210 |
| Email: |
inquiries@lgmpharma.com |
GYKI 52466 HYDROCHLORIDE manufacturers
- GYKI-52466
-
- $1520.00
-
2026-05-11
- CAS:102771-26-6
- Purity:
- Supply Ability: 10g
|
| | GYKI 52466 HYDROCHLORIDE Basic information |
| Product Name: | GYKI 52466 HYDROCHLORIDE | | Synonyms: | gyki52466;4-(8-METHYL-9H-1,3-DIOXOLO[4,5-H][2,3]BENZODIAZEPIN-5-YL)-BENZENAMINE HYDROCHLORIDE;GYKI 52466 HYDROCHLORIDE;4-(8-Methyl-(9H)-1,3-dioxolo[4.5-h][2.3]benzodiazepine-5-yl)benzenaminehydrochloride;GYKI52466HCl;1-(4-Aminophenyl)-4-methyl-7,8-(methylenedioxy)-5H-2,3-benzodiazepine;4-(8-Methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-5-yl)aniline;1-(p-Aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine hydrochloride | | CAS: | 102771-26-6 | | MF: | C17H16ClN3O2 | | MW: | 329.78 | | EINECS: | | | Product Categories: | Amines, Aromatics, Heterocycles, Pharmaceuticals, Intermediates & Fine Chemicals | | Mol File: | 102771-26-6.mol |  |
| | GYKI 52466 HYDROCHLORIDE Chemical Properties |
| Boiling point | 472.8±45.0 °C(Predicted) | | density | 1.39 | | storage temp. | Desiccate at RT | | solubility | DMSO: 0.39 mg/mL | | form | solid | | pka | 8.14±0.20(Predicted) | | color | yellow |
| | GYKI 52466 HYDROCHLORIDE Usage And Synthesis |
| Uses | 4-(8-Methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)benzenamine is a non-competitive AMPA receptor antagonist and was found to have therapeutic potential for cocaine addiction treatment. | | Definition | ChEBI: GYKI 52466 is a benzodiazepine. | | Biological Activity | Selective non-competitive AMPA receptor antagonist (IC 50 values are 10-20, ~ 450 and >> 50 μ M for AMPA- , kainate- and NMDA-induced responses respectively). Skeletal muscle relaxant and orally-active anticonvulsant. Has anti-proliferative effects in transformed cells. Also available as part of the AMPA Receptor Tocriset™ . Also available as part of the Kainate Receptor Tocriset™ . | | in vivo | GYKI 52466 (intraperitoneal injection; 1.76-13.2 mg/kg; once) treatment provides potent anticonvulsant protection against sound-induced seizures in DBA/2 mice[2]. | Animal Model: | Male and female DBA/2 mice tested for sound-induced seizure responses[2] | | Dosage: | 1.76-13.2 mg/kg | | Administration: | Intraperitoneal injection; 1.76-13.2 mg/kg; once | | Result: | Observed Maximal anticonvulsant protection after the i.p. treatment (5-15 min ). |
| | IC 50 | Kainate Receptor: 11 μM (IC50) | | storage | room temperature (desiccate) |
| | GYKI 52466 HYDROCHLORIDE Preparation Products And Raw materials |
|